News articles about Align Technology (NASDAQ:ALGN) have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Align Technology earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 45.6014080016468 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- BioScrip (BIOS) Gains on CORE Initiatives, Competition Rife (finance.yahoo.com)
- Zacks.com featured highlights: Gray Television, Align Technology, SolarEdge Technologies, Nova Measuring Instruments and Brooks Automation (finance.yahoo.com)
- Uptrend Call Working As Align Technology Stock Rises 78.1% (ALGN) (mysmartrend.com)
- Align Technology, Inc. (ALGN) Shares Bought by NGAM Advisors LP (overnewsmagazine.com)
- Align Technology, Inc. (ALGN) Updates Q3 Earnings Guidance (ismboard.com)
A number of equities research analysts have recently weighed in on ALGN shares. Piper Jaffray Companies restated a “buy” rating and issued a $176.00 price objective on shares of Align Technology in a report on Friday, July 28th. Morgan Stanley restated an “overweight” rating and issued a $175.00 price objective on shares of Align Technology in a report on Monday, June 19th. They noted that the move was a valuation call. Northcoast Research restated a “buy” rating and issued a $186.00 price objective (up from $164.00) on shares of Align Technology in a report on Wednesday, June 21st. Stifel Nicolaus reiterated a “buy” rating and set a $200.00 price target (up from $145.00) on shares of Align Technology in a report on Friday, June 23rd. Finally, Leerink Swann reiterated an “outperform” rating and set a $199.00 price target (up from $194.00) on shares of Align Technology in a report on Friday, July 28th. Ten research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $174.40.
Shares of Align Technology (ALGN) traded up 1.36% on Friday, reaching $173.56. 719,970 shares of the company’s stock were exchanged. The company’s 50 day moving average is $159.49 and its 200-day moving average is $129.70. The stock has a market cap of $13.91 billion, a price-to-earnings ratio of 59.44 and a beta of 1.55. Align Technology has a one year low of $83.27 and a one year high of $176.84.
Align Technology (NASDAQ:ALGN) last issued its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.12. The company had revenue of $356.50 million during the quarter, compared to the consensus estimate of $343.43 million. Align Technology had a return on equity of 23.87% and a net margin of 19.18%. Align Technology’s revenue was up 32.3% on a year-over-year basis. During the same period last year, the company earned $0.62 earnings per share. On average, analysts anticipate that Align Technology will post $3.40 EPS for the current year.
In other news, VP Sreelakshmi Kolli sold 1,000 shares of Align Technology stock in a transaction on Tuesday, May 30th. The stock was sold at an average price of $144.00, for a total transaction of $144,000.00. Following the completion of the sale, the vice president now directly owns 23,785 shares in the company, valued at $3,425,040. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Joseph Lacob sold 50,000 shares of Align Technology stock in a transaction on Wednesday, May 31st. The stock was sold at an average price of $144.98, for a total value of $7,249,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 54,874 shares of company stock valued at $7,950,701. 2.00% of the stock is owned by corporate insiders.
Align Technology Company Profile
Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.
Receive News & Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.